Investment
Features
FeesSafety
Academy
More
Pluang+

Over 100,000 Georgian wine bottles use Cardano QR codes for digital provenance verification

Protocol Fundamentals
19 Oct 2026
Tokenpost
View Source
Neutral
Over 100,000 Georgian wine bottles use Cardano QR codes for digital provenance verification

A Georgian wine program has tagged over 100,000 bottles from 30+ wineries with QR codes linked to Cardano blockchain for provenance verification. Launched in partnership with Georgia's National Wine Agency and others, the system lets buyers scan codes to access supply-chain data stored off-chain but verified on Cardano. This enhances transparency and helps assure authenticity, though it doesn't guarantee the wine inside matches the records. The Cardano Foundation's open-source OriginateNavio platform powers the project, aiming to reduce counterfeiting and boost consumer confidence in Georgian wine.

The Cardano wine traceability program tagging over 100,000 Georgian bottles provides context for readers interested in blockchain applications. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 20, 2026 06:02 WIB: out of 50 major cryptocurrencies, 42 rose and 7 fell today. Notable movers include BAL (Balancer) with a price of Rp16.297 and a 1-day change of +11.14%, EOS (EOS.IO) at Rp12.649 with +8.13%, and CRV (Curve DAO Token) at Rp6.647 with +7.85%, though CRV saw a Pluang order activity heavily skewed to 99% Sell / 1% Buy and a typical hold time of 62 days.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
3 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
3 hours ago
Nvidia commits nearly $10B to boost Europe's AI, backing four German startups and partnering with German industry.

Nvidia commits nearly $10B to boost Europe's AI, backing four German startups and partnering with German industry.

Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...

Market News
Bullish
4 hours ago
Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals advances Phase 3 trial for diabetic foot infection with positive safety and efficacy signals.

Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App